When RT was combined with dual checkpoint blockade (anti-PD-L1 plus anti-CTLA-4), further improvements in complete responses (CRs) and survival were achieved in a preclinical model of breast cancer (RT plus anti-CTLA-4 resistant cell line). The gene discussed is CTLA4; the disease is breast cancer.